Definium Therapeutics (NASDAQ:DFTX) Receives Buy Rating from Canaccord Genuity Group

Posted by on Jun 16th, 2026

Definium Therapeutics (NASDAQ:DFTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Canaccord Genuity Group in a note issued to investors on Tuesday,Benzinga reports. They currently have a $38.00 price target on the stock. Canaccord Genuity Group’s target price points to a potential upside of 60.00% from the company’s previous close.

DFTX has been the subject of a number of other reports. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of Definium Therapeutics in a report on Thursday, April 23rd. Wolfe Research initiated coverage on Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price target for the company. Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a report on Thursday, April 16th. Leerink Partners boosted their price target on Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Finally, Piper Sandler reissued an “overweight” rating and issued a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and an average price target of $37.92.

Check Out Our Latest Stock Report on Definium Therapeutics

Definium Therapeutics Price Performance

DFTX traded down $0.02 during trading on Tuesday, reaching $23.75. 352,613 shares of the stock were exchanged, compared to its average volume of 1,871,060. The business’s 50 day moving average price is $22.38 and its two-hundred day moving average price is $18.06. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -9.54 and a beta of 2.37. Definium Therapeutics has a 1 year low of $6.34 and a 1 year high of $26.25.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, equities research analysts anticipate that Definium Therapeutics will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. CenterBook Partners LP acquired a new stake in Definium Therapeutics during the third quarter worth about $1,880,000. Boxer Capital Management LLC acquired a new stake in Definium Therapeutics during the third quarter worth about $1,928,000. Royce & Associates LP acquired a new stake in Definium Therapeutics during the third quarter worth about $955,000. Rosalind Advisors Inc. increased its stake in Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after acquiring an additional 330,000 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Definium Therapeutics during the third quarter worth about $654,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Read More

Analyst Recommendations for Definium Therapeutics (NASDAQ:DFTX)

Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.